Home > Insider Trading > Filing (0000899243-20-032584)

Filing Details

Accession Number:: 0000899243-20-032584
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-02 20:00:09
Reporting Period:: 2020-12-01

Accepted Time:: 2020-12-02 20:00:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1746473	Pliant Therapeutics Inc.	PLRX	Pharmaceutical Preparations (2834)	474272481

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1809204	Lamont Keith Cummings	C/O Pliant Therapeutics, Inc. 260 Littlefield Avenue South San Francisco CA 94080	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-12-01	11,591	$2.08	34,712	No	4	M	Direct
Common Stock	Acquisiton	2020-12-01	7,143	$6.22	41,855	No	4	M	Direct
Common Stock	Disposition	2020-12-01	1,139	$28.24	40,716	No	4	S	Direct
Common Stock	Disposition	2020-12-01	1,848	$29.07	38,868	No	4	S	Direct
Common Stock	Disposition	2020-12-01	14,901	$30.21	24	No	4	S	Direct
Common Stock	Disposition	2020-12-01	846	$30.72	23,121	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-12-01	11,591	$0.00	11,591	$2.08
Common Stock	Stock Option (right to buy)	Disposition	2020-12-01	7,143	$0.00	7,143	$6.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
194,597		2029-01-23	No	4	M	Direct
35,698		2030-03-30	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.63 to $28.61, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.675 to $29.655, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.685 to $30.65, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.698 to $30.775, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date.